Targeted oncology drugs · Brain-penetrant candidates · Out-licensing
Voronoi
A biotech developing precision targeted anticancer drugs, out-licensing brain-penetrant candidates to global pharma. KOSDAQ large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
310210.KQ Updated Jul 11, 2026 2 AI consumers· 2 recurring
Annual return · 2026-09-04'23+34.4%'24+150.7%'25+160.2%YTD-31.7%
Money in ▸·
Voronoi
▸ Money out·
Financials & Segments
- Segments · Targeted anticancer drugs · Licensing-out
Revenue from
No refined links yet.
Pays to
No refined links yet.